David is the president, CEO and director of Indigo. He is a serial entrepreneur who has founded and built three innovative companies in the last 20 years, leading the last two through successful IPOs to multibillion-dollar market capitalizations and raising over $1.2bn while generating significant returns for investors.
David was most recently CEO and co-founder of Anacor Pharmaceuticals (NASDAQ: ANAC), a biopharmaceutical company discovering and developing novel small-molecule therapeutics to treat infectious and inflammatory diseases. The company was acquired by Pfizer (NYSE: PFE) in 2016 for approximately $5.2bn.
David previously co-founded and served as CEO of Chemdex (NASDAQ: CMDX), later creating its parent company Ventro Corporation (NASDAQ: VNTR), a business-to-business marketplace focused on the life sciences industry. At its peak, Ventro was valued at $11bn and was later sold to Nexprise.
David is the founder and chairman of the San Francisco-based digital health startup Better Therapeutics (formerly known as FareWell) and a board director of the human microbiome company Evelo Biosciences.
In 2000, David was named Entrepreneur of the Year in Northern California by Ernst & Young. He holds an MBA from Harvard Business School and a BS in chemical engineering from the University of Tulsa. He also attended the United States Air Force Academy, where he was a National Merit Scholar.